

**DECLARATION OF JOINT WORKING BETWEEN OXFORD AHSN AND
ASTRAZENECA UK LTD**

Oxford AHSN and AstraZeneca UK Ltd are engaged in a Joint Working Project entitled “Identification and Review of Patients at High Risk of Heart Failure and Code Cleansing in Practices in Areas of High Deprivation Project”.

The aims and objectives of the project are to;

- Identify diagnosed heart failure patients not on the QOF register. Ensure these patients are captured in the ongoing heart failure clinical review cycle.
- Using a novel risk stratification tool (developed by Interface Clinical Services), Identify undiagnosed heart failure patients from a high-risk patient pool, including those with type 2 diabetes, atrial fibrillation, prior MI, +/- BAME, hypertension + 1 other risk factor, +/- previously recorded oedema or breathlessness. Screen these patients for heart failure and ensure diagnosis and optimal management, including reviewing management of heart failure risk factors.
- Increase HF prevalence
- Increase HF primary care reviews
- Increased number of patients on optimal therapy (as per local and NICE recommended guidelines)
- Increase new HF diagnoses
- Reduced unplanned hospitalisation for HF

The project will run from December 2020 to August 2021. Both parties have contributed resources to the initiative.